Oppenheimer analyst Matt Biegler raised the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $100.00 (from $90.00) while maintaining an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE